The MedTech specialized in non-invasive physiological monitoring instruments for laboratory animals.

Etisense is a French biomedical engineering company based in Lyon, specialized in developing and commercializing physiological monitoring instruments for laboratory animals. The journey started at TIMC-IMAG laboratory from Grenoble-Alpes University, within a multidisciplinary  team of scientists specialized in physiology and signal processing. The company was created with the idea that physiological monitoring should be simple and non-invasive to face the challenges of a modern and ethical medical research.

From the beginning of its adventure, Etisense is constantly improving its solutions. Today, our product ranges combine textile engineering, high performance sensors and electronics, advanced signal processing algorythms and modern software experience with full web technologies. As we believe in a global approach to achieve performant physiological monitoring, collaborations are helpful and welcome to serve your projects.

Our mission is to develop new ways to monitor physiological functions based on connected textiles. Our ambition is to cover a wide range of applications from animal / preclinical research towards veterinary medicine and human pathologies or well-being. 


In september 2023, Etisense has concluded a partnership with Data Sciences International (DSI), the pre-clinical division of Harvard Bioscience, for the exclusive distribution of our DECRO jacketed external telemetry solution in the United States, Canada, the United Kingdom and Ireland. In the European Union, Etisense will continue to market its solution.

This collaboration will give access to the jacketed telemetry for small animals to a greater number of researchers. To know more, consult the related press release here.

Co-development partnerships

2023 - Etisense collaborates with ERBC in the development of DECRO for marmosets, an highly attractive model for preclinical in vivo pharmacology, safety studies and toxicology assessment.

logo charles river laboratories

2020 - Etisense is partner with Charles River in the development of DECRO for the study of cardiac and respiratory functions in juvenile minipigs for toxicology studies.

Sanofi Pharma

2019 - Sanofi Safety-Pharmacology department and Etisense signed a co-development partnership agreement to test, give improvement input and validate scientifically DECRO in their environment.

Etisense is committed to animal welfare and ethics while focusing at providing better science


3Rs contribution

By developing non-invasive physiological monitoring solutions for small mammals, Etisense takes into account the constraints and environment of researchers using animals in their research programs. 

STAL 2019

Chantal Autissier Prize AFSTAL 2019

Our commitment towards ethics and better science has been recognized by the award of the Chantal Autissier Prize attributed by the AFSTAL Board Members once a year to a project promoting these values.

Etisense has made the choice to manufacture DECRO in France, in the Auvergne Rhône-Alpes region, and welcomes the commitment of its industrial partners in electronics and textiles to supply the most reliable products for your studies.

Management team

Timothé Flenet

Timothé FLENET

President - Scientific Director

Charles EYNARD

Chief Technical Officer

Corinne SIMON

Chief Business Officer

They support us

DECRO benefited from a "maturation" and "incubation" innovation program from the SATT Linksium public incubator located in Grenoble and has been supported by funding from SATT Linksium and Carnot-LSI during development phases.


Etisense was awarded the ILAB programme in 2019 to accelerate the development of the DECRO solution.

Etisense is supported by the Headstart program of EIT Health aiming at shortening the time-to-market for life-changing products and services.


The company has been supported by AURA region to support commercial development.

Logo LyonBioPole

 Etisense is also a member of the Lyonbiopole competitive cluster ecosystem since its incorporation.